EA201100358A1 - Дабигатран для чрескожной хирургической катетеризации сердца - Google Patents

Дабигатран для чрескожной хирургической катетеризации сердца

Info

Publication number
EA201100358A1
EA201100358A1 EA201100358A EA201100358A EA201100358A1 EA 201100358 A1 EA201100358 A1 EA 201100358A1 EA 201100358 A EA201100358 A EA 201100358A EA 201100358 A EA201100358 A EA 201100358A EA 201100358 A1 EA201100358 A1 EA 201100358A1
Authority
EA
Eurasian Patent Office
Prior art keywords
dabigatran
intertegual
heart
surgical catheterization
catheterization
Prior art date
Application number
EA201100358A
Other languages
English (en)
Russian (ru)
Inventor
Пол А. Рейлли
Original Assignee
Бёрингер Ингельхайм Интернациональ Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41258283&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201100358(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Бёрингер Ингельхайм Интернациональ Гмбх filed Critical Бёрингер Ингельхайм Интернациональ Гмбх
Publication of EA201100358A1 publication Critical patent/EA201100358A1/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30Nitrogen atoms not forming part of a nitro radical
    • C07D235/32Benzimidazole-2-carbamic acids, unsubstituted or substituted; Esters thereof; Thio-analogues thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
EA201100358A 2008-08-19 2009-08-17 Дабигатран для чрескожной хирургической катетеризации сердца EA201100358A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9001808P 2008-08-19 2008-08-19
PCT/EP2009/060592 WO2010020602A1 (en) 2008-08-19 2009-08-17 Dabigatran for percutaneous interventional cardiac catheterisation

Publications (1)

Publication Number Publication Date
EA201100358A1 true EA201100358A1 (ru) 2011-10-31

Family

ID=41258283

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201100358A EA201100358A1 (ru) 2008-08-19 2009-08-17 Дабигатран для чрескожной хирургической катетеризации сердца

Country Status (19)

Country Link
US (1) US20110301201A1 (enExample)
EP (1) EP2328580A1 (enExample)
JP (1) JP2012500245A (enExample)
KR (1) KR20110044230A (enExample)
CN (1) CN102123707A (enExample)
AR (1) AR073077A1 (enExample)
AU (1) AU2009284217A1 (enExample)
BR (1) BRPI0917507A2 (enExample)
CA (1) CA2734794A1 (enExample)
CL (1) CL2011000361A1 (enExample)
CO (1) CO6290686A2 (enExample)
EA (1) EA201100358A1 (enExample)
EC (1) ECSP11010825A (enExample)
IL (1) IL210005A0 (enExample)
MA (1) MA32563B1 (enExample)
MX (1) MX2011001612A (enExample)
NZ (1) NZ591108A (enExample)
TW (1) TW201022235A (enExample)
WO (1) WO2010020602A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2358368A1 (en) 2008-11-11 2011-08-24 Boehringer Ingelheim International GmbH Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved safety profile over conventional warfarin therapy
EA201201202A1 (ru) * 2010-03-01 2013-04-30 Рациофарм Гмбх Пероральная фармацевтическая композиция, содержащая этексилат дабигатрана
SG10201502484SA (en) 2010-03-30 2015-05-28 Verseon Corp Multisubstituted aromatic compounds as inhibitors of thrombin
CN102391250B (zh) * 2011-08-29 2013-06-19 石药集团欧意药业有限公司 一种达比加群酯化合物、制备方法及其药物组合物
CN102558153A (zh) * 2012-02-08 2012-07-11 北京阜康仁生物制药科技有限公司 达比加群酯的新药用盐及其制备方法
CN103420994B (zh) * 2012-05-24 2016-04-06 天津药物研究院 作为前药的达比加群酯衍生物及其制备方法和用途
CN103420985B (zh) * 2012-05-24 2015-09-23 天津药物研究院 作为前药的达比加群酯衍生物及其制备方法和用途
CN103420982B (zh) * 2012-05-24 2015-07-08 天津药物研究院 达比加群酯衍生物及其制备方法和用途
CN103420984B (zh) * 2012-05-24 2015-07-08 天津药物研究院 作为前药的达比加群酯衍生物及其制备方法和用途
CN103524559B (zh) * 2012-07-05 2016-09-28 西藏海思科药业集团股份有限公司 多取代4-甲氨基苯甲脒的酯衍生物及其制备方法和用途
CN103539779B (zh) * 2012-07-13 2016-12-21 四川海思科制药有限公司 一种达比加群酯的羟基取代苯磺酸盐及其制备方法和用途
CA2886094A1 (en) * 2012-09-28 2014-04-03 Ranbaxy Laboratories Limited Process for the preparation of dabigatran etexilate or pharmaceutically acceptable salt thereof
US9399616B2 (en) 2012-10-22 2016-07-26 Boehringer Ingelheim International Gmbh Process for the manufacture of 4-aminobenzoamidine dihydrochloride
ES2702182T3 (es) 2013-03-15 2019-02-27 Verseon Corp Compuestos aromáticos multisustituidos como inhibidores de la serina proteasa
HK1214252A1 (zh) 2013-03-15 2016-07-22 Verseon Corporation 作為凝血酶抑制劑的鹵代吡唑
BR112017004704A2 (pt) 2014-09-17 2018-01-23 Verseon Corp composto, composição farmacêutica, e, método para tratar uma doença ou distúrbio em um indivíduo
SG11201706411YA (en) 2015-02-27 2017-09-28 Verseon Corp Substituted pyrazole compounds as serine protease inhibitors
CN113164765A (zh) 2018-07-13 2021-07-23 维颂国际公司 凝血酶抑制剂、制剂及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE540943T1 (de) * 2002-03-07 2012-01-15 Boehringer Ingelheim Pharma 3-ä(2-ää4-(hexyloxycarbonylamino-imino-methyl)- phenylaminoümethylü-1-methyl-1h-benzimidazol-5- carbonyl)-pyridin-2-yl-aminoü-propionsäure- ethylester methansulfonat
EP1807086A1 (en) * 2004-10-25 2007-07-18 Boehringer Ingelheim International GmbH Use of dipyridamole in combination with antithrombotics for treatment and prevention of thromboembolic diseases
AU2007276205A1 (en) * 2006-07-17 2008-01-24 Boehringer Ingelheim International Gmbh New indications for direct thrombin inhibitors in the cardiovascular field
WO2008009640A1 (en) * 2006-07-17 2008-01-24 Boehringer Ingelheim International Gmbh New paediatric indications for direct thrombin inhibitors
US20100087488A1 (en) * 2006-10-10 2010-04-08 Boehringer Ingelheim International Gmgh Physiologically Acceptable Salts of 3-[(2--1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester

Also Published As

Publication number Publication date
US20110301201A1 (en) 2011-12-08
CL2011000361A1 (es) 2011-06-17
WO2010020602A1 (en) 2010-02-25
ECSP11010825A (es) 2011-03-31
IL210005A0 (en) 2011-02-28
CO6290686A2 (es) 2011-06-20
JP2012500245A (ja) 2012-01-05
MA32563B1 (fr) 2011-08-01
AU2009284217A1 (en) 2010-02-25
KR20110044230A (ko) 2011-04-28
TW201022235A (en) 2010-06-16
EP2328580A1 (en) 2011-06-08
AR073077A1 (es) 2010-10-13
BRPI0917507A2 (pt) 2015-11-17
CA2734794A1 (en) 2010-02-25
NZ591108A (en) 2012-11-30
CN102123707A (zh) 2011-07-13
MX2011001612A (es) 2011-03-04

Similar Documents

Publication Publication Date Title
EA201100358A1 (ru) Дабигатран для чрескожной хирургической катетеризации сердца
CY1124117T1 (el) Ετεροκυκλικες αλκυνυλοβενζολικες ενωσεις και ιατρικες συνθεσεις και χρησεις αυτων
UY30500A1 (es) Compuestos de azabencimidazolilo
UY31189A1 (es) Compuestos heterocíclicos
EA201200049A1 (ru) 1,3-дизамещенные производные имидазолидин-2-она в качестве ингибиторов cyp 17
MX2015017964A (es) Inhibidores de bromodominio.
EA201100971A1 (ru) Производные пиримидининдола для лечения злокачественного новообразования
MX2015012432A (es) Inhibidores piridinicos de la cinasa cdk9.
MX380928B (es) Inhibidores de kras g12c.
PE20221914A1 (es) Compuestos de benzaldehido sustituidos y metodos para su uso en incrementar la oxigenacion del tejido
EA201490949A1 (ru) Ингибиторы киназ
CY1119007T1 (el) Συνθεσεις και μεθοδοι αγωγης πνευμονικης υπερτασης
UA109010C2 (en) Morpholino pyrividines and their use in therapy
UA124922C2 (uk) Модулятори ядерного транспорту та їх застосування
EA201491607A1 (ru) Модуляторы толлподобных рецепторов
EA201591363A1 (ru) Аналоги тиадиазола и способы лечения состояний, связанных с дефицитом smn
EA201390934A1 (ru) Композиции и способы модулирования fxr
EA201201263A1 (ru) Фармацевтическая композиция, содержащая этексилат дабигатрана
ATE530524T1 (de) Substituierte sulfonamid-derivate
UA106636C2 (uk) Морфолінотіазоли як позитивні алостеричні модулятори альфа 7
MX2012004311A (es) Derivados de ciclohexano spiro condensados como inhibidores de lipasa sensible a hormonas (hsl) utiles en el tratamiento de diabetes.
DOP2011000134A (es) Lactamas como inhibidores de beta secretasa
MX392150B (es) Moduladores de receptores canabinoides.
BR112014009910A2 (pt) formulações de sal de meglumina de ácido 1-(5,6-dicloro-1h-benzo[d]imidazol-2-il)-1h-pirazol-4-carboxílico
EA201001196A1 (ru) Соединения 4-пиридинона и их применение для лечения рака